Clinical trials: Colorectal Adenocarcinoma Metastatic in the Liver
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic…
- Conditions
- Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer
- Trial name
- SPKTAHC (NCT07636785)
- Testing
- VMD-102
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- VM Discovery, Inc.
Colorectal Neoplasms, Liver Neoplasms
A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver
The purpose of this study is to determine the effectiveness of radioactive microsphere infusion as a treatment for liver metastases from colon or rectal cancer.
- Trial name
- NCT01098422
- Testing
- Yttrium-90 Radioactive Resin Microspheres
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Tony Reid, M.D., Ph.D.
Liver Metastases, Mucinous Adenocarcinoma of the Colon
Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver
This phase I trial studies the side effects and best dose of irinotecan-eluting beads in treating patients with colon or rectal cancer that has spread to the liver and does not respond to treatment with standard therapy.
- Conditions
- Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer
- Trial name
- NCT02110953
- Testing
- irinotecan-eluting beads, hepatic artery embolization
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fox Chase Cancer Center
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Colorectal Adenocarcinoma Metastatic in the Liver, Liver Metastasis Colon Cancer
Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis
The goal of this clinical trial is to assess how many patients with initially inoperable colorectal liver metastasis are able to have a liver surgery after treatment with hepatic artery infusion chemotherapy and standard of care…
- Conditions
- Colorectal Adenocarcinoma Metastatic in the Liver, Liver Metastasis Colon Cancer, Liver Metastases From Colorectal Cancer, Liver Metastases of Colorectal Cancer
- Trial name
- HAIP-6192 (NCT07764497)
- Testing
- Floxuridine (FUDR)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Sunnybrook Health Sciences Centre
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Colorectal Cancer, Metastatic Cancer
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00936832
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- France
- Sponsor
- Federation Francophone de Cancerologie Digestive